Italian health authorities and international researchers have confirmed that GLP-1 analog drugs are safe and effective for treating obesity.

These findings arrive as Italy faces high rates of overweight and obesity, necessitating proven pharmacological options to reduce long-term health complications. The move signals a shift toward integrating these medications into formal clinical management under strict regulation.

The Italian Medicines Agency (AIFA) said the treatments are not a shortcut but are effective drugs that require prescription and medical supervision for their use [1]. This guidance aligns with the first update to the 2025 guidelines on the pharmacological management of obesity and its complications, published by the European Association for the Study of Obesity (EASO) [2].

Support for these medications is based on dozens of authoritative studies [3]. However, clinical data shows varying levels of efficacy between different analogs. According to clinical study data, 48% of patients treated with tirzepatide lose more than 20% of their initial weight, while 27% of those treated with semaglutide achieve the same result [4].

The need for such interventions is highlighted by regional data in Emilia-Romagna, where 32% of the population is overweight and 11.3% are obese [5]. While the drugs are clinically effective, accessibility remains a point of contention. Some reports indicate the state does not cover the cost, leaving many patients unable to afford the treatment [6].

Medical professionals said these drugs must be used as part of a comprehensive health plan. AIFA continues to advocate for a conscious use of these medications to ensure patient safety and prevent misuse for cosmetic weight loss.

“Non una scorciatoia, ma farmaci efficaci che richiedono però prescrizione e supervisione medica per il loro utilizzo.”

The endorsement of GLP-1 analogs by AIFA and EASO validates a pharmacological approach to a chronic disease, moving obesity treatment beyond simple lifestyle advice. However, the gap between clinical efficacy and financial accessibility suggests that while the science is settled, the public health implementation remains limited by economic barriers and the necessity of lifelong medical monitoring.